TRGNF (Transgene) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TRGNF Transgene SA TRGNF
42 GF Score
Price $0.85
GF Value $0.61
! 7 Warning Signs
View Full Analysis

What is Transgene Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

TRGNF
42GF Score
Transgene SA TRGNF
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Transgene (TRGNF) Overvalued in 2026?

Based on GuruFocus' analysis, Transgene stock appears to be overvalued. The current stock price of $0.85 is trading 39.3% above its estimated GF Value™ of $0.61.

Key valuation signals for TRGNF:

  • Dividends Received:
  • GF Value™: $0.61 vs. price of $0.85 (39.3% above fair value)
  • GF Score™: 42/100 with 7 warning signs

No single metric tells the full story. See the TRGNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Transgene Business Description

Address 400, Boulevard Gonthier d’Andernach, Parc d’Innovation, Illkirch-Graffenstaden, Strasbourg, FRA, 67400
Transgene SA is a biotechnology company that designs and develops virus based immunotherapy products focused on the development of individualized therapeutic vaccines against cancers. The flagship program, TG4050, is an individualized therapeutic vaccine based on the myvac platform. The company also has other viral vector-based programs, including BT-001, an oncolytic virus based on the Invir.IO viral backbone, which is in clinical development. In addition, it conducts discovery and preclinical work, aimed at developing novel immunotherapies.
42GF Score

Get the complete analysis for TRGNF

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.85
Price
$0.61
GF Value